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Cross-Canada Anaphylaxis Registry: comparing triggers and management of anaphylaxis in emergency medical service in Quebec over a 4-year period In the community, administration of epinephrine using an epinephrine auto-injector (EAI) is the first-line of treatment. Quick and correct EAI usage is critical in an allergic emergency. METHODS: This crossover study evaluated the usability of two currently-marketed EAIs (Auvi-QÒ 0.15 mg and EpiPen JrÒ 0.15 mg) during a simulated allergic emergency. Inexperienced adult participants were asked to simulate administering epinephrine to a child-sized manikin (patient) using only the instructions for use on the EAIs. Participants did not receive EAI training or information leaflets. The EAI study devices were trainers with no needles or medication and were labeled to resemble Auvi-Q and EpiPen Jr. RESULTS: Ninety-six participants were evaluated (54 female/42 male; mean age 43613.6 years). Significantly more participants completed epinephrine administration per device instructions with Auvi-Q versus EpiPen Jr (85% versus 20%, respectively; p<0.0001). For Auvi-Q, the most frequent use error was not holding 2 seconds. For EpiPen Jr, the most frequent use errors were not swinging, not having the orange tip against outer thigh, and not holding 3 seconds. Fourteen participants (15%) simulated injection into their digit/palm when using EpiPen Jr; whereas, no participants simulated injection into their digit/palm when using Auvi-Q (p50.0001). CONCLUSIONS: In this allergic emergency scenario, significantly more participants safely and correctly used Auvi-Q than EpiPen Jr. Use errors, including unintentional digital injections that pose a user safety risk and could result in epinephrine not being administered to the patient, should be considered when evaluating EAIs.
